A kinetic model for redox-active film based biophotoelectrodes.

Redox-active films are advantageous matrices for the immobilization of photosynthetic proteins, due to their ability to mediate electron transfer as well as to achieve high catalyst loading on an electrode for efficient generation of electricity or solar fuels. A general challenge arises from various charge recombination pathways along the light-induced electron transfer chain from the electrode to the charge carriers for electricity production or to the final electron acceptors for solar fuel formation. Experimental methods based on current measurement or product quantification are often unable to discern between the contributions from the photocatalytic process and the detrimental effect of the short-circuiting reactions. Here we report on a general electrochemical model of the reaction-diffusion processes to identify and quantify the "bottlenecks" present in the fuel or current generation. The model is able to predict photocurrent-time curves including deconvolution of the recombination contributions, and to visualize the corresponding time dependent concentration profiles of the product. Dimensionless groups are developed for straightforward identification of the limiting processes. The importance of the model for quantitative understanding of biophotoelectrochemical processes is highlighted with an example of simulation results predicting the effect of the diffusion coefficient of the charge carrier on photocurrent generation for different charge recombination kinetics.

Shear-sensitive nanocapsule drug release for site-specific inhibition of occlusive thrombus formation.

Essentials Vessel stenosis due to large thrombus formation increases local shear 1-2 orders of magnitude. High shear at stenotic sites was exploited to trigger eptifibatide release from nanocapsules. Local delivery of eptifibatide prevented vessel occlusion without increased tail bleeding times. Local nanocapsule delivery of eptifibatide may be safer than systemic antiplatelet therapies. SUMMARY: Background Myocardial infarction and stroke remain the leading causes of mortality and morbidity. The major limitation of current antiplatelet therapy is that the effective concentrations are limited because of bleeding complications. Targeted delivery of antiplatelet drug to sites of thrombosis would overcome these limitations. Objectives Here, we have exploited a key biomechanical feature specific to thrombosis, i.e. significantly increased blood shear stress resulting from a reduction in the lumen of the vessel, to achieve site-directed delivery of the clinically used antiplatelet agent eptifibatide by using shear-sensitive phosphatidylcholine (PC)-based nanocapsules. Methods PC-based nanocapsules (2.8 × 1012 ) with high-dose encapsulated eptifibatide were introduced into microfluidic blood perfusion assays and into in vivo models of thrombosis and tail bleeding. Results Shear-triggered nanocapsule delivery of eptifibatide inhibited in vitro thrombus formation selectively under stenotic and high shear flow conditions above a shear rate of 1000 s-1 while leaving thrombus formation under physiologic shear rates unaffected. Thrombosis was effectively prevented in in vivo models of vessel wall damage. Importantly, mice infused with shear-sensitive antiplatelet nanocapsules did not show prolonged bleeding times. Conclusions Targeted delivery of eptifibatide by shear-sensitive nanocapsules offers site-specific antiplatelet potential, and may form a basis for developing more potent and safer antiplatelet drugs.

Regulatory use of (Q)SARs in toxicological hazard assessment strategies.

In 2001, the European Commission published a policy statement ("White Paper") on future chemicals regulation and risk reduction that proposed the use of non-animal test systems and tailor-made testing approaches, including (Q)SARs, to reduce financial costs and the number of test animals employed. The authors have compiled a database containing data submitted within the EU chemicals notification procedure. From these data, (Q)SARs for the prediction of local irritation/corrosion and/or sensitisation potential were developed and published. These (Q)SARs, together with an expert system supporting their use, will be submitted for official validation and application within regulatory hazard assessment strategies. The main features are: two sets of structural alerts for the prediction of skin sensitisation hazard classification as defined by the European risk phrase R43, comprising 15 rules for chemical substructures deemed to be sensitising by direct action with cells or proteins, and three rules for substructures acting indirectly, i.e., requiring biochemical transformation; a decision support system (DSS) for the prediction of skin and/or eye lesion potential built from information extracted from our database. This DSS combines SARs defining reactive chemical substructures relevant for local lesions to be classified, and QSARs for the prediction of the absence of such a potential. The role of the BfR database, and (Q)SARs derived from it, in the use of current and future (EU) testing strategies for irritation and sensitisation is discussed.

Determination of intracerebral structures using osseous reference points for computer-aided stereotactic operations.

Computer-aided sterotactic neurosurgery can be improved and simplified by using craniocerebral parameters for the calculation of subcortical target points and avoiding an air-filling of the ventricles. This was achieved by selecting 403 pneumo-encephalographic studies at random, measuring the craniocerebral parameters according to age and sex. There is a correlation between the bony cranium and the brain axis. We established a formula and a table to determine in the plain X-ray the entrance of the foramen of Monroi with a standard deviation of +/- 1.5 mm and the inclination of the intracerebral basic line we used (foramen Monroi-commissura posterior). With this information various subcortical targets can be determined by means of computer programs.